H04*Update of REVEL: A randomized, double-blind, phase III...

Annals of Oncology 2015 / 10 Vol. 26; Iss. suppl 6

H04*Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line (2L) treatment of stage IV non-small cell lung cancer (NSCLC) including subgroup analysis of histology

Bidoli, P., Cappuzzo, F., Favaretto, A., Alabiso, O., Tiseo, M., Chella, A., Gebbia, V., Pizzuti, L., Paz-Ares, L., Perol, M., Garon, E., Lee, P., Zimmermann, A., Cuyun Carter, G., Migliorino, M.R.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv343.04
Date:
October, 2015
File:
PDF, 35 KB
english, 2015
Conversion to is in progress
Conversion to is failed